Stine U. Mikkelsen

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.

The risk of myelodysplastic syndrome and acute myeloid leukemia by metformin use and type 2 diabetes status - a Danish nation-wide cohort study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 04, 2024

Portosystemic Hepatic Encephalopathy Scores (PHES) differ between Danish and German healthy populations despite their geographical and cultural similarities.

Portosystemic Hepatic Encephalopathy Scores (PHES) differ between Danish and German healthy populations despite their geographical and cultural similarities.

Journal: Metabolic brain disease

Published: February 08, 2024

LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.

LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.

Journal: Clinical epigenetics

Published: December 21, 2022

The role of vitamin C in epigenetic cancer therapy.

The role of vitamin C in epigenetic cancer therapy.

Journal: Free radical biology & medicine

Published: December 05, 2020

Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance.

Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance.

Journal: Haematologica

Published: June 13, 2020

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Journal: Haematologica

Published: January 16, 2020

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Journal: European journal of haematology

Published: April 29, 2019

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Journal: Cancer medicine

Published: January 02, 2018

Showing 1-8 of 8

Last Updated: 09/26/2026